Skip to content
Screener

Medtronic MDT Loss Contingency Accrual

Loss Contingency Accrual at other companies

Boston Scientific logo
Boston ScientificBSX
Neuropace, Inc. logo
Neuropace, Inc.NPCE

Other financials

Income statement

See full
Revenue$9.8B+9.9%
Gross profit$6.4B+10.9%
Operating income$1.9B+30.4%
Net income$1.2B+17.8%
EPS (diluted)$0.97+18.3%

Balance sheet

See full
Cash & equivalents$1.9B-12.1%
Total debt$29.2B-1.6%
Total equity$49.5B+3.0%
Total assets$93.0B+1.5%

Cash flow

See full
Operating cash flow$2.6B+1.8%
CapEx$488.0M+6.3%
Free cash flow$2.1B+0.8%

Valuation

See full
Market cap$109.98B-3.9%
Enterprise value$137.24B-3.3%
P/E22.9×-1.7×
P/S-0.3×

Profitability

See full
Gross margin65%-0.3pp
Operating margin17.8%0.0pp
Net margin13.2%-0.7pp
FCF margin14.9%-0.5pp

Returns & leverage

See full
Return on equity9.8%+0.4pp
Debt / equity0.6×0.0×
Current ratio2.1×+0.3×

Where this comes from

Reported directly by Medtronic in its filing.

Tagged under the XBRL concept us-gaap:LossContingencyAccrualAtCarryingValue.

The source filing: Medtronic’s 10-Q, filed February 24, 2026.

Filed
Feb 24, 2026, 4:18 PM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-011107

The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges, net in the consolidated statements of income. The Company recognized $62 million and $89 million of certain litigation charges during the three and nine months ended January 23, 2026, respectively. The Company recognized $22 million and $104 million of certain litigation charges during the three and nine months ended January 24, 2025, respectively. At January 23, 2026 and April 25, 2025, accrued litigation was approximately $0.2 billion and $0.4 billion, respectively. The ultimate cost to the Company with respect to this litigation is difficult to predict, and the cost of any litigation, including litigation subject to accruals, could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other accrued expenses and other liabilities on the consolidated balance sheets.

Item 1. Financial Statements

FAQ

What is Medtronic's loss contingency accrual?
Medtronic (MDT) reported loss contingency accrual of $200M in Q4 2025.
How has Medtronic's loss contingency accrual changed year-over-year?
Medtronic's loss contingency accrual decreased by 0.0% year-over-year, from $200M to $200M.
What is the long-term trend for Medtronic's loss contingency accrual?
Over 4 years (2021 to 2025), Medtronic's loss contingency accrual has grown at a 0.0% compound annual growth rate (CAGR), from $400M to $400M.

Ask your AI about Medtronic's loss contingency accrual.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude